Alumis (ALMS) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• Alumis is set to release its Q2 2025 earnings on August 12th, with expected earnings of ($1.11) per share and revenue of $1.80 million.
• The stock is currently trading at $4.09 and has a 50-day moving average of $3.45, showing a significant range of $2.76 to $13.11 over the past year.
• Analysts have mixed opinions on Alumis, with several recommending a "buy" rating, while target prices vary between $14.00 and $25.00.

Alumis (NASDAQ:ALMS - Get Free Report) is projected to announce its Q2 2025 earnings results before the market opens on Tuesday, August 12th. Analysts expect Alumis to post earnings of ($1.11) per share and revenue of $1.80 million for the quarter.

Alumis (NASDAQ:ALMS - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($1.82) EPS for the quarter, missing analysts' consensus estimates of ($1.47) by ($0.35). On average, analysts expect Alumis to post $-9 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Alumis Price Performance

ALMS stock opened at $4.37 on Thursday. Alumis has a 1 year low of $2.76 and a 1 year high of $13.11. The company's 50-day moving average is $3.45 and its 200-day moving average is $4.80.

Institutional Trading of Alumis

A number of large investors have recently added to or reduced their stakes in ALMS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Alumis by 64.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,535 shares of the company's stock worth $77,000 after purchasing an additional 4,926 shares during the period. Rhumbline Advisers boosted its holdings in Alumis by 21.7% in the 1st quarter. Rhumbline Advisers now owns 16,543 shares of the company's stock valued at $102,000 after purchasing an additional 2,949 shares during the period. Jane Street Group LLC purchased a new position in shares of Alumis during the 1st quarter valued at $111,000. Finally, Goldman Sachs Group Inc. raised its position in shares of Alumis by 24.0% in the first quarter. Goldman Sachs Group Inc. now owns 61,645 shares of the company's stock worth $378,000 after buying an additional 11,949 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on ALMS shares. Guggenheim upgraded Alumis to a "buy" rating and set a $18.00 target price on the stock in a report on Tuesday, June 10th. Oppenheimer decreased their price objective on Alumis from $26.00 to $25.00 and set an "outperform" rating for the company in a report on Thursday, May 15th. Wells Fargo & Company started coverage on Alumis in a research note on Friday, July 25th. They set an "overweight" rating and a $17.00 price objective on the stock. Finally, HC Wainwright reiterated a "buy" rating and issued a $14.00 target price on shares of Alumis in a report on Friday, July 25th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $19.80.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.